TRICARE Transplant and immunosuppressant appeal

Why TRICARE denies transplant and immunosuppressant

TRICARE is the U.S. Department of Defense health program covering active-duty servicemembers, retirees, and eligible family members. Appeals are governed by 32 CFR Part 199, administered by regional contractors (Humana Military and TriWest), with final review by the Defense Health Agency (DHA).

For transplant and immunosuppressant specifically: Solid-organ transplant patients depend on continuous immunosuppressive therapy to prevent rejection. UNOS/OPTN guidelines establish that immunosuppressant regimens generally cannot be switched without significant clinical risk. Denials of transplant evaluation, listing, surgery, or maintenance immunosuppression are among the most clinically urgent appeals.

The law that controls this appeal

UNOS/OPTN clinical guidelines govern eligibility and continuity of care; Medicare Part B covers post-transplant immunosuppressants by statute.

What TRICARE denies for transplant and immunosuppressant

The transplant and immunosuppressant services most often denied:

Transplant evaluation and waitlisting
Transplant surgery (kidney, liver, heart, lung)
Specific brand of immunosuppressant (tacrolimus, mycophenolate, sirolimus)
Generic-to-brand switches denied
Anti-rejection biologic therapy
Out-of-network transplant centers

Why transplant and immunosuppressant claims get denied

A typical TRICARE transplant and immunosuppressant denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:

Plan claims patient not medically eligible for transplant
Step therapy on immunosuppressants
Plan formulary forces switch from brand to generic
Out-of-network transplant facility
Post-transplant complications denied as unrelated

The TRICARE appeal process

Appeal levels: Contractor reconsideration, formal review by DHA, then independent hearing (above the amount-in-controversy threshold), then DHA Director final decision.

Carrier timing: 90 days from denial for reconsideration; 60 days from each subsequent adverse decision for the next level. Urgent / pre-authorization timelines compress to 72 hours.

Transplant timing: Urgent appeals: 72 hours. Standard: 30 days for prior auth, 60-180 days filing window. Transplant cases routinely qualify for expedited urgent review.

What we know about TRICARE: TRICARE rules are federal, state DOI external review does not apply. We brief appeals against 32 CFR Part 199 and the TRICARE Operations Manual specifically.

Common TRICARE denial patterns for transplant and immunosuppressant

Regional contractor reconsideration first. TRICARE appeals begin with reconsideration by the regional managed care support contractor, Humana Military (East) or TriWest (West). The reconsideration request must be in writing and is typically due within 90 days of the initial denial.
Formal review by DHA. After contractor reconsideration, members can request a formal review by the Defense Health Agency. This step is the gateway to a hearing and is the prerequisite to any further federal review.
Independent hearing for higher-dollar cases. TRICARE provides an independent hearing for appeals meeting a minimum amount-in-controversy threshold. The hearing officer's recommendation goes to the DHA Director for a final agency decision.

How to win your TRICARE transplant and immunosuppressant appeal

Strategy for transplant and immunosuppressant: Cite UNOS/OPTN clinical guidelines for transplant eligibility and continuity of care. For immunosuppressant switch denials, attach the treating transplant team's letter documenting the rejection risk from any regimen change. Many plans have specific transplant carve-out networks (Centers of Excellence), confirm in-network status of the specific center before assuming OON. Medicare Part B covers immunosuppressants post-transplant under federal law.

Filed against TRICARE, that strategy rides on this procedural spine:

Procedural-rights anchor. Every TRICARE denial triggers ERISA § 503 or 45 C.F.R. § 147.136 procedural rights. The cover letter invokes these in the opening paragraph to lock the timeline and force criteria disclosure.
Criteria-disclosure demand. TRICARE frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
Controlling-standard citation. UNOS/OPTN clinical guidelines govern eligibility and continuity of care; Medicare Part B covers post-transplant immunosuppressants by statute.
Treating-provider attestation. A letter from the treating physician addressing each criterion in TRICARE's own policy language. This is the single strongest evidentiary element.
Requested action. A specific demand to reverse the transplant and immunosuppressant denial and approve the service, not a general "please reconsider."

Documents you'll need for your TRICARE transplant and immunosuppressant appeal

Denial letter
Transplant team's letter and treatment plan
UNOS / center listing documentation
Lab values supporting transplant indication
Prior immunosuppressant trial history (if relevant)

What a transplant and immunosuppressant appeal can recover

Typical recovery for transplant and immunosuppressant cases runs $10,000 - $1,000,000+. The exact figure depends on the specific service and your plan's contracted rates.

TRICARE transplant and immunosuppressant appeals: frequently asked questions

Can I appeal your TRICARE transplant or immunosuppressant denial?

Yes, and these are among the most clinically urgent appeals. Cite UNOS/OPTN clinical guidelines for eligibility and continuity of care, and request expedited 72-hour review where rejection risk is in play.

Can TRICARE force me to switch immunosuppressants?

You can contest it. UNOS/OPTN guidance is that immunosuppressant regimens generally cannot be switched without significant rejection risk; attach your transplant team's letter documenting that risk for any forced brand-to-generic or formulary switch.

Is my transplant center in network?

Many plans use specific transplant Centers of Excellence networks. Confirm the center's status before assuming it is out of network, because a carve-out network often covers a center that the general directory does not list.

Are post-transplant drugs covered by Medicare?

Yes. Medicare Part B covers immunosuppressive drugs following a covered transplant by federal law, which is a direct counter to a maintenance-immunosuppression denial.

What Apellica does for TRICARE transplant and immunosuppressant appeals

We file appeals against TRICARE specifically configured to its internal review process. Every transplant and immunosuppressant appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.

Cost: $0 upfront. We work on contingency for TRICARE appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.

Start your TRICARE transplant and immunosuppressant appeal

Submit a 2-minute intake. A senior reviewer responds within one business day with the specific appeal strategy for your case.

Start free appeal review →

How to appeal your TRICARE transplant and immunosuppressant denial